We investigated the biodistribution and radiation dosimetry of the PET amyloid imaging
agent 11C-PIB (11C-6-OH-BTA-1)(where BTA is benzothiazole) in humans. Previous …

The regulatory mechanism of exploratory INDs established in 2006 by the US Food and
Drug Administration (FDA) is useful for the evaluation of tracer dose radiopharmaceutical …

PURPOSE: The compound (E)-4-(2-(6-(2-(2-(2-18F-fluoroethoxy) ethoxy) ethoxy) pyridin-3-
yl) vinyl)-N-methylbenzenamine ([18F] AV-45) is a novel radiopharmaceutical capable of …

We have characterized the biodistribution and dosimetry of 18F-3′-F-6-OH-BTA1 (18F-
GE067), a newly developed radioligand to visualize and quantify amyloid burden, in healthy …

187 Objectives:[C-11] PIB has been successfully employed to assess brain amyloid-beta
(Aβ) deposition in Alzheimer's disease (AD). Our ongoing efforts to develop an [F-18] …

PET studies have been performed using the amyloid binding radiotracer Pittsburgh
Compound B (PIB). Previous quantitative analyses using arterial blood showed that the …

β-Amyloid (Aβ) imaging has great potential to aid in the diagnosis of Alzheimer disease and
the development of therapeutics. The radiation dosimetry of Aβ radioligands may influence …

Technical factors play a critical role in the production of best-quality amyloid PET images for
interpretation. This article provides specific instructions and general technical information …

In the past 10 years, the development and evaluation of PET tracers for imaging fibrillar
amyloid in the human brain in patients with Alzheimer's disease (AD) has been very …

Background The amyloid neuritic plaque is considered to be a toxic collection of amyloid-ß
protein found in brain tissue in Alzheimer's disease. A neutral analogue of the amyloid …